503 related articles for article (PubMed ID: 28874331)
21. Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease.
Hellstrom WJG; Tan RBW; Liu G
Urology; 2017 Aug; 106():237.e9-237.e14. PubMed ID: 28502596
[TBL] [Abstract][Full Text] [Related]
22. Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.
Hellstrom WJG; Tue Nguyen HM; Alzweri L; Chung A; Virasoro R; Tapscott A; Ziegelmann M; Trost L; Gelbard M
J Urol; 2019 Apr; 201(4):777-782. PubMed ID: 30672843
[TBL] [Abstract][Full Text] [Related]
23. Long-term Curvature Deformity Characterization in Men Previously Treated With Collagenase Clostridium Histolyticum for Peyronie's Disease, Subgrouped by Penile Plaque Calcification.
Goldstein I; McLane MP; Xiang Q; Wolfe HR; Hu Y; Gelbard MK
Urology; 2020 Dec; 146():145-151. PubMed ID: 32896582
[TBL] [Abstract][Full Text] [Related]
24. Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease.
Yafi FA; Anaissie J; Zurawin J; Sikka SC; Hellstrom WJ
J Sex Med; 2016 Apr; 13(4):684-9. PubMed ID: 27045265
[TBL] [Abstract][Full Text] [Related]
25. Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling.
Fernández-Pascual E; González-García FJ; Angulo J; Cerezo E; Quintana LM; Turo J; Martínez-Ballesteros C; Carballido J; Martínez-Salamanca JI
BJU Int; 2019 Dec; 124(6):1055-1062. PubMed ID: 31033130
[TBL] [Abstract][Full Text] [Related]
26. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol.
Abdel Raheem A; Johnson M; Abdel-Raheem T; Capece M; Ralph D
Sex Med Rev; 2017 Oct; 5(4):529-535. PubMed ID: 28874327
[TBL] [Abstract][Full Text] [Related]
27. Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie's disease: a review of the literature.
Masterson TA; Rezk A; Ramasamy R
World J Urol; 2020 Feb; 38(2):279-285. PubMed ID: 31250098
[TBL] [Abstract][Full Text] [Related]
28. Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.
Dhillon S
Drugs; 2015 Aug; 75(12):1405-12. PubMed ID: 26201462
[TBL] [Abstract][Full Text] [Related]
29. Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond.
Mills SA; Gelbard MK
World J Urol; 2020 Feb; 38(2):269-277. PubMed ID: 31168744
[TBL] [Abstract][Full Text] [Related]
30. Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease.
Gelbard M; Hellstrom WJ; McMahon CG; Levine LA; Smith T; Tursi J; Kaufman G; Goldstein I
J Sex Med; 2013 Nov; 10(11):2822-31. PubMed ID: 24112401
[TBL] [Abstract][Full Text] [Related]
31. Collagenase Clostridium histolyticum for the pharmacological management of Peyronie's disease.
Anaissie J; Powers MK; Hellstrom WJ; Yafi FA
Drugs Today (Barc); 2015 Aug; 51(8):457-68. PubMed ID: 26380384
[TBL] [Abstract][Full Text] [Related]
32. Treatment-related Outcomes for Patients With Atypical Peyronie's Disease Using Xiaflex Injections.
El-Khatib FM; Osman MM; Kopelevich A; Towe M; Yafi FA
Urology; 2020 Sep; 143():153-158. PubMed ID: 32590080
[TBL] [Abstract][Full Text] [Related]
33. Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
Yang KK; Bennett N
Urology; 2016 Aug; 94():143-7. PubMed ID: 27211926
[TBL] [Abstract][Full Text] [Related]
34. Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease.
Abdel Raheem A; Johnson M; Ralph D; Garaffa G
Minerva Urol Nefrol; 2018 Aug; 70(4):380-385. PubMed ID: 29761688
[TBL] [Abstract][Full Text] [Related]
35. Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.
Hoy SM
Clin Drug Investig; 2020 Jan; 40(1):83-92. PubMed ID: 31628593
[TBL] [Abstract][Full Text] [Related]
36. Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence.
Traore EJ; Wang W; Yafi FA; Hellstrom WJ
Ther Adv Urol; 2016 Jun; 8(3):192-202. PubMed ID: 27247629
[TBL] [Abstract][Full Text] [Related]
37. Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A 'Real World' Clinical Perspective.
Anaissie J; Hellstrom WJ; Yafi FA
Drugs; 2016 Oct; 76(16):1523-1528. PubMed ID: 27770352
[TBL] [Abstract][Full Text] [Related]
38. Safety of Collagenase Clostridium histolyticum Injection Therapy for Peyronie Disease in Patients Continuing Antiplatelet or Anticoagulant Therapy.
Amighi A; Regets KV; Nork JJ; Mendhiratta N; Mills JN; Eleswarapu SV
J Sex Med; 2020 Feb; 17(2):353-356. PubMed ID: 31866126
[TBL] [Abstract][Full Text] [Related]
39. Intralesional Injection of Collagenase Clostridium histolyticum May Increase the Risk of Late-Onset Penile Fracture.
Beilan JA; Wallen JJ; Baumgarten AS; Morgan KN; Parker JL; Carrion RE
Sex Med Rev; 2018 Apr; 6(2):272-278. PubMed ID: 28923562
[TBL] [Abstract][Full Text] [Related]
40. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.
Jordan GH
J Sex Med; 2008 Jan; 5(1):180-7. PubMed ID: 18173766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
